When Roche Group acquired biotechnology company Genentech for $46.8 billion in March 2009, it was faced with integrating the companies’ U.S. operations — and two in-house legal departments — as efficiently as possible.
The Swiss pharmaceutical maker met this challenge in large part through the Roche Law Department’s innovative use of technology, which General Counsel and Chief Compliance Officer Frederick Kentz calls “instrumental in our harmonization efforts.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
